Automation of the In Vitro Fertilization Laboratory

ConditionsInfertilityART
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorConceivable Life Sciences

About this trial

Enrolled patients will undergo an Assisted Reproductive technology (ART) treatment using intracytoplasmic sperm injection (ICSI, the direct injection of a single sperm cell into an oocyte) as the method of insemination. In this prospective cohort study, patients' sperm, eggs, and embryos will be processed using an automated system called AURA (Conceivable Life Sciences), which consists of five subsystems. Specifically, sperm samples will be prepared for fertilization using the subsystem C:SPERM. Cumulus-oocyte complexes (COCs) containing the oocytes will be isolated from follicular fluid using the subsystem C:EGG. One out of every four COCs will be removed from the AURA system at random and processed according to the local treatment clinic's standard operating procedure. All other COCs will continue automated procedures and will be denuded, fertilized, incubated, and vitrified using the AURA subsystems C:EGG. C:ICSI, C:CULTURE and C:VIT, respectively. All automated procedures will be conducted under the supervision of a laboratory manager, who can intervene, address any potential anomalies, and override any steps undertaken by the automated AURA system. The study aims to deliver a descriptive evaluation of the AURA system, including assessing the device's performance, defined by its level of automation, efficiency, and throughput. As a secondary objective, the study aims to characterize the clinical performance of each of AURA's subsystems and correlate this performance against pre-established benchmarks in a non-inferiority statistical analysis. Finally, the study seeks to collect technical data related to AURA's hardware and software operation.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Informed consent signed by the patients before treatment.

Medical indication to perform assisted reproductive technology.

Body mass index between 20 and 29 kg/m2 (female participants only).

Anti-Müllerian Hormone (AMH) value of at least 1.5 ng/mL.

Disqualifiers

Patients diagnosed with recurrent pregnancy loss.

Inaccessible ovaries for puncture.

History of total or partial fertilization failure in a previous fertility treatment.

History of repeated implantation failure defined as three previous unsuccessful embryo transfers.

Trial design

Design model

Single group

Treatments tested in this trial

  • AURA assisted ART treatment

    Device

    The AURA device consists of five subsystems, which will operate in logical sequence to deliver comprehensive automation of the laboratory element of an ART cycle. The AURA treatment begins after ovarian stimulation, on the day of egg collection. A sperm sample is provided on the same day of egg collection. Sperm samples will be prepared by the C:SPERM subsystem. Follicular fluid obtained at egg collection will be processed by the C:EGG subsystem. 3 out of every 4 cumulus-oocyte complexes (COCs) recovered will be denuded by the C:EGG subsystem. These denuded eggs will be fertilized by the C:ICSI subsystem, incubated in the C:CULTURE subsystem and all resulting suitable embryos will be vitrified by the C:VIT subsystem. Thawed embryos may be used in conventional frozen embryo transfers.

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: AURA assisted ART treatmentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Autonomy

proportion of tasks successfully completed by the AURA system without requiring human intervention.

Time frame
9 months
2

Procedural timings

time employed by the AURA system to complete each of its automated tasks.

Time frame
9 months

Secondary outcomes

1

Sperm motility post preparation

proportion of sperm cells displaying motility (progressive) following sperm preparation.

Time frame
9 months
2

Denudation survival rate

proportion of oocytes that do not lyse or degenerate at the end of automated egg discovery and denudation.

Time frame
9 months
3

ICSI damage rate

Proportion of oocytes that lyse or degenerate within 24 hours after ICSI.

Time frame
9 months
4

Normal fertilization rate

proportion of oocytes with two pronuclei (and two polar bodies if assessable) 16 hrs after ICSI.

Time frame
9 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Conceivable Life Sciences

Lead sponsor

Hope Fertility Center

Collaborator

Reina Madre

Collaborator

Nascere

Collaborator